Tag: GCP compliance

Documenting Make-vs-Buy Strategy & RFP Process for Audits, Health Authority Queries and Due Diligence Documenting Make-vs-Buy Strategy & RFP Process for Audits, Health Authority Queries and Due Diligence In today’s regulated clinical trial environment, organizations face a pressing need to justify their strategic approach towards vendor selection and project execution. This often translates into a…

Read More “Documenting Make-vs-Buy Strategy & RFP Process for Audits, Health Authority Queries and Due Diligence” »

Digital Tools and Automation That Transform Make-vs-Buy Strategy & RFP Process in Clinical Development In the rapidly evolving landscape of clinical development, organizations must make critical decisions regarding resource allocation. One significant consideration is whether to develop in-house capabilities or engage external services—commonly referred to as the make-vs-buy strategy. The integration of digital tools and…

Read More “Digital Tools and Automation That Transform Make-vs-Buy Strategy & RFP Process in Clinical Development” »

Case Studies: Make-vs-Buy Strategy & RFP Process That Rescued High-Risk Studies and Vendors Case Studies: Make-vs-Buy Strategy & RFP Process That Rescued High-Risk Studies and Vendors Introduction to the Make-vs-Buy Strategy in Clinical Trials As clinical trials become increasingly complex, the decision to make or buy certain services and technologies has significant implications for operational…

Read More “Case Studies: Make-vs-Buy Strategy & RFP Process That Rescued High-Risk Studies and Vendors” »

Integrating Make-vs-Buy Strategy & RFP Process With QMS, Risk Registers and Governance Committees The successful execution of clinical trials hinges on effective management and strategic decision-making. As clinical operations professionals in the US, UK, and EU navigate complex regulatory environments, integrating a make-vs-buy strategy with the request for proposal (RFP) process becomes imperative. This comprehensive…

Read More “Integrating Make-vs-Buy Strategy & RFP Process With QMS, Risk Registers and Governance Committees” »

Aligning Make-vs-Buy Strategy & RFP Process With ICH E6(R3), GCP and Quality-by-Design Principles Aligning Make-vs-Buy Strategy & RFP Process With ICH E6(R3), GCP and Quality-by-Design Principles The decision to either “make” or “buy” in clinical research settings, particularly during the RFP (Request for Proposal) process, is a critical step that can influence the success of…

Read More “Aligning Make-vs-Buy Strategy & RFP Process With ICH E6(R3), GCP and Quality-by-Design Principles” »

Make-vs-Buy Strategy & RFP Process Checklists for Clinical Operations and Vendor Governance Teams Make-vs-Buy Strategy & RFP Process Checklists for Clinical Operations and Vendor Governance Teams Introduction The clinical research industry is characterized by a need for agility, precision, and compliance. In navigating the complexities of clinical trials, organizations often face a crucial decision: whether…

Read More “Make-vs-Buy Strategy & RFP Process Checklists for Clinical Operations and Vendor Governance Teams” »

Common Pitfalls in Make-vs-Buy Strategy & RFP Process—and How to Avoid Regulatory Findings Common Pitfalls in Make-vs-Buy Strategy & RFP Process—and How to Avoid Regulatory Findings In the highly regulated landscape of clinical trials, the strategic choice between making an in-house solution or buying from an external vendor is paramount. The implications of this make-vs-buy…

Read More “Common Pitfalls in Make-vs-Buy Strategy & RFP Process—and How to Avoid Regulatory Findings” »

Using KPIs and SLAs to Optimize Make-vs-Buy Strategy & RFP Process Across CROs and Service Providers The decision-making process surrounding clinical trial execution often involves complex evaluations regarding whether to conduct certain activities in-house (make) or to outsource to Contract Research Organizations (CROs) and other service providers (buy). This make-vs-buy strategy is critical in the…

Read More “Using KPIs and SLAs to Optimize Make-vs-Buy Strategy & RFP Process Across CROs and Service Providers” »

Make-vs-Buy Strategy & RFP Process for Decentralized, Hybrid and Data-Heavy Clinical Trials In the evolving landscape of clinical trials, particularly as they become increasingly decentralized and data-heavy, clinical operations, regulatory affairs, and medical affairs professionals must navigate a critical choice: whether to make or buy the resources, technology, and expertise required to execute a successful…

Read More “Make-vs-Buy Strategy & RFP Process for Decentralized, Hybrid and Data-Heavy Clinical Trials” »